

Benedic N. Ippolito

March, 2023

Senior Fellow
American Enterprise Institute

<https://www.aei.org/scholar/benedic-n-ippolito/>

PROFESSIONAL EXPERIENCE

American Enterprise Institute

Senior Fellow, 2020-Present

Research Fellow, 2015-2020

University of Wisconsin-Madison

Honorary Research Fellow, Department of Population Health Sciences, 2015-2018

RESEARCH FIELDS

Public Finance, Health Economics

EDUCATION

Ph.D., Economics, University of Wisconsin-Madison, 2015 (*Committee: John Karl Scholz (chair), John Mullahy, Christopher Taber*)

M.S., Economics, University of Wisconsin-Madison, 2012

B.A., Mathematics and Economics, Emory University, *Summa Cum Laude*, 2010

PEER-REVIEWED RESEARCH

“Drug Pricing Decisions and Insurance Coverage: Evidence from Medicare Part D” (with Joseph Levy). In preparation for special issue of *Healthcare* (Editor: Mark Pauly).

“The Influence of Medicare Part D on the List Pricing of Brand Drugs” (with Joseph Levy). Forthcoming. *Health Services Research*.

“Health Insurance, Medical Debt, and Spillovers to Broader Financial Health” (with Christa Gibbs and Michael Batty). *Health Economics*. 31(5): 689-728. 2022.

“Branded Price Variation in the U.S. Drug Market, 2010-2019” (with Joseph Levy). *Value in Health*. 24(9): 1237-1240. 2021.

“The Impact of the COVID-19 Pandemic on Elective Inpatient Surgical Admissions: Evidence from Maryland” (with Joe Levy, Kevin Wang, and Amit Jain). *Journal of Surgical Research*. 268: 389-393. 2021.

“The Costs of Delayed Generic Drug Entry: Evidence From A Controversial Prostate Cancer Drug Patent” (with David Miller, Ben Davies, and Inma Hernandez). In Press. *General Journal of Internal Medicine*.

“Medicaid and Fiscal Federalism During the COVID-19 Pandemic” (with Jeffrey Clemens and Stan Veuger). *Public Budgeting & Finance*. 41: 94-109. 2021. (Ungated NBER Working Paper)

“Hospital revenue under Maryland’s total cost of care model during the COVID-19 pandemic, March through July 2020” (with Joseph Levy and Amit Jain). *JAMA*. 325(4):398-400. 2021.

“Abandoning List Prices in Drug Reimbursement Did Not Impact Spending in Medicaid” (with Joseph Levy and Gerard Anderson). *Health Affairs*. 39(7): 1202-1209. 2020.

“Surprise Medical Bills: How to Protect Patients and Make Care More Affordable” (with David Hyman and Charles Silver). *Georgetown Law Review*. 108(6): 1655-1677. 2020.

“Uncompensated Care and the Collapse of Hospital Payment Regulation: An Application of the Tinbergen Rule” (with Jeffrey Clemens). *Public Finance Review*. 47(6):1002-1041. 2019. (Ungated NBER Working Paper)

“Unlike Medical Spending, Medical Bills In Collections Decrease With Patients’ Age” (with Michael Batty and Christa Gibbs). *Health Affairs*. 37(8): 1257-1264. 2018.

“Implications of Medicaid Financing Reform for State Government Budgets” (with Jeffrey Clemens). *Tax Policy and the Economy*. Volume 32. 2018 (Ungated NBER Working Paper).

“Financial Incentives, Hospital Care, and Health Outcomes: Evidence From Fair Pricing Laws,” (with Michael Batty). *American Economic Journal: Economic Policy*. 9(2): 28-56. 2017.

“Mystery of the Chargemaster: Examining the Role of Hospital List Prices in What Patients Pay” (with Michael Batty). *Health Affairs*. 36(4): 689-696. 2017.

“The Selection Effects of Tied Health Insurance Contracts”. *AEI Economic Policy Working Paper 2015-14*

POLICY WRITING

“Procompetitive Health Care Reform Options for a Divided Congress” (with Loren Adler). Policy Brief. American Enterprise Institute and the Brookings Institution. March 16, 2023.

“How Medicare Shapes Drug Pricing” (with Joseph Levy). *AEIdeas*. February 7, 2023.

“Initial Implications from the Pricing of Humira Biosimilars” (with Scott Gottlieb). *AEIdeas*. February 1, 2023.

“How Should Policymakers Respond To Growth In Cost Sharing That Often Goes Unpaid?” (with Boris Vabson). *Health Affairs Forefront*. January 18, 2023.

“What Is (Or Isn’t) The Problem With PBMs?” *American Enterprise Institute*. November 8, 2022.

“Estimating Maximum Prices Under Medicare Negotiation in Part D”. *AEIdeas*. September 21, 2022.

“The Consequential Tradeoffs Embedded in Congress New Drug Pricing Bill” (with Scott Gottlieb). *American Enterprise Institute*. August 4, 2022.

“A New Fix for Insulin Prices Could Do More Harm than Good” (with Joseph Levy). *AEIdeas*. July 15, 2022.

“Do Higher Hospital Prices Reflect Greater Investments in Quality?” *Tradeoffs*. June 21, 2022.

“Comments to the Federal Trade Commission on Impact of Prescription Benefit Managers Business Practices”. April 22, 2022.

“Best Practices Using SSR Health Net Drug Pricing Data” (with Joseph Levy). *Health Affairs Forefront*. March 10, 2022.

“New evidence suggests a lack of cost-shifting in prescription drug markets” (with Loren Adler). *Incidental Economist*. February 17, 2022.

[“Do drugmakers “revenue target”? Evidence from the differential timing of biosimilar entry across markets”](#) (with Loren Adler and Conrad Milhaupt). *AEI Economic Perspectives*. January 18, 2022.

[“Comments on No Surprises Act rulemaking: Part II”](#) (with Loren Adler and Matthew Fiedler). December 6, 2021.

[“Increasing cost pressures in the commercial health care market.”](#) September 27, 2021. American Enterprise Institute.

[“Comments on No Surprises Act rulemaking: Part I”](#) (with Loren Adler and Matthew Fiedler). September 1, 2021.

[“Equal weighting is a poor framework for arbitration decisions under the No Surprises Act”](#) (with Matthew Fiedler and Loren Adler). Brookings Institution. June 24, 2021.

[“The variability of US drug prices: Lessons for policy debates.”](#) *AEIdeas*. May 18, 2021.

[“Recommendations for Implementing the No Surprises Act”](#) (with Matthew Fielder and Loren Adler). Brookings Institution. March 16, 2021.

[“Understanding the No Surprises Act”](#) (with Loren Adler, Matthew Fiedler, Paul Ginsburg, Mark Hall, and Erin Trish). Brookings Institution. February 4, 2021.

[“COVID-19 and nursing homes: National updates and early evidence on the second wave”](#) (with Alex Brill), *AEIdeas*. August 10, 2020.

[“COVID-19 and nursing homes: Understanding state-level variation”](#) (with Alex Brill), *AEIdeas*. June 26, 2020.

[“Nursing home COVID-19 data are getting better”](#) (with Alex Brill), *AEIdeas*. June 19, 2020.

[“COVID-19 and nursing homes: Examining new national data”](#) (with Alex Brill), *AEIdeas*. June 10, 2020.

[“Comment on ‘The Potential Pitfalls of Combating Surprise Billing’”](#) (with David Hyman). *Regulation* 42 (2019): 40.

[“Understanding the impact of the newly proposed Senate drug pricing legislation on manufacturers’ investment decisions”](#) (with Scott Gottlieb and Abigail Keller). *AEIdeas*. September 9, 2019.

[“The Economics of Biologic Drugs: A Further Response to Bach et al.”](#) (with Alex Brill). Health Affairs Blog. August 8, 2019.

[“Evaluating the Senate Finance Committee Proposal to Restructure Medicare Part D”](#) (with Scott Gottlieb). *AEIdeas*. July 24, 2019.

[“Biologics Are Not Natural Monopolies”](#) (with Alex Brill). Health Affairs Blog. July 2, 2019.

[“Network Matching: An Attractive Solution To Surprise Billing”](#) (with Loren Adler and Matthew Fiedler). Health Affairs Blog. May 23, 2019.

[“Solving Surprise Medical Billing”](#) (with David Hyman). *AEI Economic Perspectives*. March 20, 2019.

[“Cost-Reducing Health Policies: A Response to Chairman Alexander and the Senate Committee on Health, Education, Labor, and Pensions”](#) (with Henry Aaron, Loren Adler, Joseph Antos, James Capretta, Matthew Fiedler, Paul Ginsburg, and Alice Rivlin). March 1, 2019.

[“The Effect of Tax Reform on Medical Deductions”](#) (with Alex Brill). *Tax Notes*. 159(7). 2018.

[“Reduced Opioid Marketing Could Limit Prescribing Information for Physicians”](#) (with Stan Veuger). *JAMA Internal Med*. 2018;178(10):1427.

[“The Basis for Compromise on Medicaid Reform and Expansion”](#) (with Joseph Antos and James Capretta). Health Affairs Blog. June 15, 2017.

CONGRESSIONAL TESTIMONY

[“Medical Debt in the United States.”](#) Senate Committee on Banking, Housing, and Urban Affairs. March 29, 2022.

[“Lowering Drug Prices and Improving Medicare.”](#) House Committee on Ways and Means. October 17, 2019.

[“Testimony on HR 3 and Other Drug Pricing Reforms”](#) House Committee Energy and Commerce. September 25, 2019.

[“Testimony on the Lower Health Care Costs Act.”](#) Senate Committee on Health, Education, Labor, and Pensions. June 18, 2019.

CONFERENCES, SEMINARS, PANELS

2022: National Governors Association, Vanderbilt University, Senate Committee on Banking, Housing, and Urban Affairs, Progressive Policy Institute, Council for Affordable Health Coverage, University of Michigan Ross School of Business, Society of Health Policy Young Professionals

2021: Vanderbilt University, ERIC Conference, Penn Leonard Davis Institute

2020: Brookings Institution, Becker Friedman Institute Health Economics Initiatives Annual Conference; American Society of Health Economists Conference; Harvard Medical School

2019: Bipartisan Policy Center; American-European Health Economics Study Group; Senate Committee on Health, Education, Labor, and Pensions; House Committee on Energy and Commerce; University of Michigan Ross School of Business; Council for Affordable Health Care; Next Steps in Health Reform 2019 Conference, American University; House Committee on Ways and Means; Agency for Healthcare Research and Quality; The Future of U.S. Healthcare: Innovation in Health Care Delivery

2018: American Society of Health Economists Conference

2017: AEI; Harrington Symposium on Health Economics, University of Texas - Austin; National Bureau of Economic Research Tax Policy and the Economy Conference; National Tax Association Annual Conference; The Brookings Institution; RAND Corporation

REFEREE ACTIVITY

American Journal of Health Economics, American Journal of Managed Care, The BMJ, George Mason University Mercatus Center, Health Affairs, Health Economics, JAMA Health Forum, JAMA Internal Medicine, Journal of Health Economics, Journal of Public Economics, Journal of Policy Analysis and Management, Journal of the Royal Statistical Society

SELECT OPINION WRITING

(Note that author does not typically choose title)

[“The Uncertain Effects of Medicare Drug Negotiation”](#). *NBC Think*. August 15, 2022.

[State and Local Governments Need Help. Pass COVID Relief Now.](#) (with Jeffrey Clemens and Stan Veuger), *The Bulwark*

[Joe Biden’s Medicare for More Mistake](#) (with Chris Pope), *Wall Street Journal*

[Get Rid of Surprise Medical Bills](#), *Wall Street Journal*

[Arbitration Not the Answer to Fix Surprise Medical Billing](#) (with David Hyman), *RealClearPolicy*

[Drug pricing conversations must take the cost of innovation into consideration](#) (with Craig Garthwaite), *STAT*

[An amuse-bouche to the impending single-payer debates](#), *AEIdeas*

A warning on health-care price setting as envisioned by AB3087 (with Jeff Clemens), *San Fransisco Chronicle*
Our Willful Ignorance on Drug Prices, *The Hill*
Tax reform might tell us whether the individual mandate really works, *AEIdeas*
Resolving the AHCA's Incoherence on Cost Discipline, *The Hill*
Making (some) sense of hospital list prices, *AEIdeas*
The little death spiral that couldn't (with Stan Veuger), *Real Clear Health*
Medicaid reform: The elephant in the room (with Jeffrey Clemens), *Real Clear Health*
The subsidy underpinning Maryland healthcare 'exceptionalism', *The Baltimore Sun*
How a Popular Provision Is Undermining the ACA Exchanges, *Inside Sources*